Cargando…

A survey on the distribution of healthy people with different anti-tumour ability

INTRODUCTION: The aim of the study was to explore the distribution of healthy people with different anti-tumour ability. MATERIAL AND METHODS: Leukocytes were separated by the Ficoll-Hypaque density gradient centrifugal method. Then they were mixed with A549, MCF-7 and Hela cells at different ratios...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yanhong, Xu, Xiaolan, Dong, Zhennan, Jiang, Chaoguang, Gao, Jin, Hu, Jinchuan, Gui, Junhao, Wang, Haibao, Tian, Yaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298353/
https://www.ncbi.nlm.nih.gov/pubmed/22419943
http://dx.doi.org/10.5114/aoms.2010.17099
_version_ 1782225989118459904
author Gao, Yanhong
Xu, Xiaolan
Dong, Zhennan
Jiang, Chaoguang
Gao, Jin
Hu, Jinchuan
Gui, Junhao
Wang, Haibao
Tian, Yaping
author_facet Gao, Yanhong
Xu, Xiaolan
Dong, Zhennan
Jiang, Chaoguang
Gao, Jin
Hu, Jinchuan
Gui, Junhao
Wang, Haibao
Tian, Yaping
author_sort Gao, Yanhong
collection PubMed
description INTRODUCTION: The aim of the study was to explore the distribution of healthy people with different anti-tumour ability. MATERIAL AND METHODS: Leukocytes were separated by the Ficoll-Hypaque density gradient centrifugal method. Then they were mixed with A549, MCF-7 and Hela cells at different ratios. The survival rate for target cells was observed and counted by Fluoroskan. Immune function for 200 healthy people was analysed by flow cytometry. RESULTS: The results obtained by confocal microscopy revealed that human blood leukocytes possessed direct anti-tumour activity. The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells. We speculated that in 200 healthy people the leukocyte capacity for killing MCF-7 cells is stronger than the leukocyte capacity for killing A549 cells and Hela cells. We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells. The number of healthy people with the strongest anti-tumour ability was highest when the target cells were MCF-7 cells. Moreover, the survival of A549, MCF-7 and Hela cells was correlated with T, B and NK lymphocytes. CONCLUSIONS: From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer.
format Online
Article
Text
id pubmed-3298353
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-32983532012-03-14 A survey on the distribution of healthy people with different anti-tumour ability Gao, Yanhong Xu, Xiaolan Dong, Zhennan Jiang, Chaoguang Gao, Jin Hu, Jinchuan Gui, Junhao Wang, Haibao Tian, Yaping Arch Med Sci Clinical Research INTRODUCTION: The aim of the study was to explore the distribution of healthy people with different anti-tumour ability. MATERIAL AND METHODS: Leukocytes were separated by the Ficoll-Hypaque density gradient centrifugal method. Then they were mixed with A549, MCF-7 and Hela cells at different ratios. The survival rate for target cells was observed and counted by Fluoroskan. Immune function for 200 healthy people was analysed by flow cytometry. RESULTS: The results obtained by confocal microscopy revealed that human blood leukocytes possessed direct anti-tumour activity. The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells. We speculated that in 200 healthy people the leukocyte capacity for killing MCF-7 cells is stronger than the leukocyte capacity for killing A549 cells and Hela cells. We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells. The number of healthy people with the strongest anti-tumour ability was highest when the target cells were MCF-7 cells. Moreover, the survival of A549, MCF-7 and Hela cells was correlated with T, B and NK lymphocytes. CONCLUSIONS: From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer. Termedia Publishing House 2010-10 2010-10-26 /pmc/articles/PMC3298353/ /pubmed/22419943 http://dx.doi.org/10.5114/aoms.2010.17099 Text en Copyright © 2010 Termedia & Banach http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research
Gao, Yanhong
Xu, Xiaolan
Dong, Zhennan
Jiang, Chaoguang
Gao, Jin
Hu, Jinchuan
Gui, Junhao
Wang, Haibao
Tian, Yaping
A survey on the distribution of healthy people with different anti-tumour ability
title A survey on the distribution of healthy people with different anti-tumour ability
title_full A survey on the distribution of healthy people with different anti-tumour ability
title_fullStr A survey on the distribution of healthy people with different anti-tumour ability
title_full_unstemmed A survey on the distribution of healthy people with different anti-tumour ability
title_short A survey on the distribution of healthy people with different anti-tumour ability
title_sort survey on the distribution of healthy people with different anti-tumour ability
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298353/
https://www.ncbi.nlm.nih.gov/pubmed/22419943
http://dx.doi.org/10.5114/aoms.2010.17099
work_keys_str_mv AT gaoyanhong asurveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT xuxiaolan asurveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT dongzhennan asurveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT jiangchaoguang asurveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT gaojin asurveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT hujinchuan asurveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT guijunhao asurveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT wanghaibao asurveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT tianyaping asurveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT gaoyanhong surveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT xuxiaolan surveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT dongzhennan surveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT jiangchaoguang surveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT gaojin surveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT hujinchuan surveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT guijunhao surveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT wanghaibao surveyonthedistributionofhealthypeoplewithdifferentantitumourability
AT tianyaping surveyonthedistributionofhealthypeoplewithdifferentantitumourability